Surprisingly, none of the liver tumors in NASH-HCC mice regressed upon anti-PD1 treatment, while tumors in non-NASH HCC cancer models were shrunk by identical regimens. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.